+1 347 708 0418
The Autologous Matrix-Induced Chondrogenesis (AMIC) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Autologous Matrix-Induced Chondrogenesis (AMIC) size is estimated to be USD 125.6 million in 2026 from USD 104.6 million in 2020, with a change XX% between 2020 and 2021. The global Autologous Matrix-Induced Chondrogenesis (AMIC) market size is expected to grow at a CAGR of 4.7% for the next five years.
Market segmentation
Autologous Matrix-Induced Chondrogenesis (AMIC) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Polylactic-Co-Glycolic Acid (PGLA)
Others
Market segment by Application, can be divided into
Knee Cartilage Repair
Hip Cartilage Repair
Elbow Cartilage Repair
Others
Market segment by players, this report covers
Anika Therapeutics, Inc.
Arthro-Kinetics
B. Braun Melsungen AG
BioTissue AG
CartiHeal
Geistlich Pharma AG
JRI Orthopaedics Ltd.
Matricel GmbH
Smith & Nephew plc
Zimmer Biomet Holdings
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Autologous Matrix-Induced Chondrogenesis (AMIC) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Autologous Matrix-Induced Chondrogenesis (AMIC), with revenue, gross margin and global market share of Autologous Matrix-Induced Chondrogenesis (AMIC) from 2019 to 2021.
Chapter 3, the Autologous Matrix-Induced Chondrogenesis (AMIC) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Autologous Matrix-Induced Chondrogenesis (AMIC) market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Autologous Matrix-Induced Chondrogenesis (AMIC) research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Autologous Matrix-Induced Chondrogenesis (AMIC)
1.2 Classification of Autologous Matrix-Induced Chondrogenesis (AMIC) by Type
1.2.1 Overview: Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Type in 2020
1.2.3 Hyaluronic Acid
1.2.4 Collagen
1.2.5 Polyethylene Glycol (PEG)
1.2.6 Polylactic-Co-Glycolic Acid (PGLA)
1.2.7 Others
1.3 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market by Application
1.3.1 Overview: Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Knee Cartilage Repair
1.3.3 Hip Cartilage Repair
1.3.4 Elbow Cartilage Repair
1.3.5 Others
1.4 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size & Forecast
1.5 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast by Region
1.5.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Region, (2016-2021)
1.5.3 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Prospect (2016-2026)
1.5.4 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Prospect (2016-2026)
1.5.6 South America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Drivers
1.6.2 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Restraints
1.6.3 Autologous Matrix-Induced Chondrogenesis (AMIC) Trends Analysis
2 Company Profiles
2.1 Anika Therapeutics, Inc.
2.1.1 Anika Therapeutics, Inc. Details
2.1.2 Anika Therapeutics, Inc. Major Business
2.1.3 Anika Therapeutics, Inc. Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.1.4 Anika Therapeutics, Inc. Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Anika Therapeutics, Inc. Recent Developments and Future Plans
2.2 Arthro-Kinetics
2.2.1 Arthro-Kinetics Details
2.2.2 Arthro-Kinetics Major Business
2.2.3 Arthro-Kinetics Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.2.4 Arthro-Kinetics Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Arthro-Kinetics Recent Developments and Future Plans
2.3 B. Braun Melsungen AG
2.3.1 B. Braun Melsungen AG Details
2.3.2 B. Braun Melsungen AG Major Business
2.3.3 B. Braun Melsungen AG Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.3.4 B. Braun Melsungen AG Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 B. Braun Melsungen AG Recent Developments and Future Plans
2.4 BioTissue AG
2.4.1 BioTissue AG Details
2.4.2 BioTissue AG Major Business
2.4.3 BioTissue AG Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.4.4 BioTissue AG Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 BioTissue AG Recent Developments and Future Plans
2.5 CartiHeal
2.5.1 CartiHeal Details
2.5.2 CartiHeal Major Business
2.5.3 CartiHeal Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.5.4 CartiHeal Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 CartiHeal Recent Developments and Future Plans
2.6 Geistlich Pharma AG
2.6.1 Geistlich Pharma AG Details
2.6.2 Geistlich Pharma AG Major Business
2.6.3 Geistlich Pharma AG Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.6.4 Geistlich Pharma AG Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Geistlich Pharma AG Recent Developments and Future Plans
2.7 JRI Orthopaedics Ltd.
2.7.1 JRI Orthopaedics Ltd. Details
2.7.2 JRI Orthopaedics Ltd. Major Business
2.7.3 JRI Orthopaedics Ltd. Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.7.4 JRI Orthopaedics Ltd. Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 JRI Orthopaedics Ltd. Recent Developments and Future Plans
2.8 Matricel GmbH
2.8.1 Matricel GmbH Details
2.8.2 Matricel GmbH Major Business
2.8.3 Matricel GmbH Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.8.4 Matricel GmbH Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Matricel GmbH Recent Developments and Future Plans
2.9 Smith & Nephew plc
2.9.1 Smith & Nephew plc Details
2.9.2 Smith & Nephew plc Major Business
2.9.3 Smith & Nephew plc Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.9.4 Smith & Nephew plc Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Smith & Nephew plc Recent Developments and Future Plans
2.10 Zimmer Biomet Holdings
2.10.1 Zimmer Biomet Holdings Details
2.10.2 Zimmer Biomet Holdings Major Business
2.10.3 Zimmer Biomet Holdings Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
2.10.4 Zimmer Biomet Holdings Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Zimmer Biomet Holdings Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Autologous Matrix-Induced Chondrogenesis (AMIC) Players Market Share
3.2.2 Top 10 Autologous Matrix-Induced Chondrogenesis (AMIC) Players Market Share
3.2.3 Market Competition Trend
3.3 Autologous Matrix-Induced Chondrogenesis (AMIC) Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Market Share by Type (2016-2021)
4.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Application (2016-2021)
5.2 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2026)
6.2 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2026)
6.3 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country
6.3.1 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2026)
6.3.2 United States Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
6.3.3 Canada Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
6.3.4 Mexico Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2026)
7.2 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2026)
7.3 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country
7.3.1 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2026)
7.3.2 Germany Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
7.3.3 France Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
7.3.5 Russia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
7.3.6 Italy Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2026)
8.2 Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2026)
8.3 Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Region
8.3.1 Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Region (2016-2026)
8.3.2 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
8.3.3 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
8.3.4 South Korea Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
8.3.5 India Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
8.3.7 Australia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2026)
9.2 South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2026)
9.3 South America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country
9.3.1 South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2026)
9.3.2 Brazil Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
9.3.3 Argentina Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2026)
10.2 Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2026)
10.3 Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country
10.3.1 Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2026)
10.3.2 Turkey Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
10.3.4 UAE Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) by Region (2016-2021)
Table 5. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Region (2021-2026)
Table 6. Anika Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Anika Therapeutics, Inc. Major Business
Table 8. Anika Therapeutics, Inc. Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 9. Anika Therapeutics, Inc. Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Arthro-Kinetics Corporate Information, Head Office, and Major Competitors
Table 11. Arthro-Kinetics Major Business
Table 12. Arthro-Kinetics Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 13. Arthro-Kinetics Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. B. Braun Melsungen AG Corporate Information, Head Office, and Major Competitors
Table 15. B. Braun Melsungen AG Major Business
Table 16. B. Braun Melsungen AG Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 17. B. Braun Melsungen AG Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. BioTissue AG Corporate Information, Head Office, and Major Competitors
Table 19. BioTissue AG Major Business
Table 20. BioTissue AG Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 21. BioTissue AG Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. CartiHeal Corporate Information, Head Office, and Major Competitors
Table 23. CartiHeal Major Business
Table 24. CartiHeal Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 25. CartiHeal Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Geistlich Pharma AG Corporate Information, Head Office, and Major Competitors
Table 27. Geistlich Pharma AG Major Business
Table 28. Geistlich Pharma AG Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 29. Geistlich Pharma AG Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. JRI Orthopaedics Ltd. Corporate Information, Head Office, and Major Competitors
Table 31. JRI Orthopaedics Ltd. Major Business
Table 32. JRI Orthopaedics Ltd. Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 33. JRI Orthopaedics Ltd. Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Matricel GmbH Corporate Information, Head Office, and Major Competitors
Table 35. Matricel GmbH Major Business
Table 36. Matricel GmbH Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 37. Matricel GmbH Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Smith & Nephew plc Corporate Information, Head Office, and Major Competitors
Table 39. Smith & Nephew plc Major Business
Table 40. Smith & Nephew plc Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 41. Smith & Nephew plc Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Zimmer Biomet Holdings Corporate Information, Head Office, and Major Competitors
Table 43. Zimmer Biomet Holdings Major Business
Table 44. Zimmer Biomet Holdings Autologous Matrix-Induced Chondrogenesis (AMIC) Product and Solutions
Table 45. Zimmer Biomet Holdings Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) by Players (2019-2021)
Table 47. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Share by Players (2019-2021)
Table 48. Breakdown of Autologous Matrix-Induced Chondrogenesis (AMIC) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Autologous Matrix-Induced Chondrogenesis (AMIC) Players Head Office, Products and Services Provided
Table 50. Autologous Matrix-Induced Chondrogenesis (AMIC) Mergers & Acquisitions in the Past Five Years
Table 51. Autologous Matrix-Induced Chondrogenesis (AMIC) New Entrants and Expansion Plans
Table 52. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) by Type (2016-2021)
Table 53. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Share by Type (2016-2021)
Table 54. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Forecast by Type (2021-2026)
Table 55. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2021)
Table 56. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Forecast by Application (2021-2026)
Table 57. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Autologous Matrix-Induced Chondrogenesis (AMIC) Picture
Figure 2. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Type in 2020
Figure 3. Hyaluronic Acid
Figure 4. Collagen
Figure 5. Polyethylene Glycol (PEG)
Figure 6. Polylactic-Co-Glycolic Acid (PGLA)
Figure 7. Others
Figure 8. Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Application in 2020
Figure 9. Knee Cartilage Repair Picture
Figure 10. Hip Cartilage Repair Picture
Figure 11. Elbow Cartilage Repair Picture
Figure 12. Others Picture
Figure 13. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Region (2016-2026)
Figure 16. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Region in 2020
Figure 17. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Autologous Matrix-Induced Chondrogenesis (AMIC) Market Drivers
Figure 23. Autologous Matrix-Induced Chondrogenesis (AMIC) Market Restraints
Figure 24. Autologous Matrix-Induced Chondrogenesis (AMIC) Market Trends
Figure 25. Anika Therapeutics, Inc. Recent Developments and Future Plans
Figure 26. Arthro-Kinetics Recent Developments and Future Plans
Figure 27. B. Braun Melsungen AG Recent Developments and Future Plans
Figure 28. BioTissue AG Recent Developments and Future Plans
Figure 29. CartiHeal Recent Developments and Future Plans
Figure 30. Geistlich Pharma AG Recent Developments and Future Plans
Figure 31. JRI Orthopaedics Ltd. Recent Developments and Future Plans
Figure 32. Matricel GmbH Recent Developments and Future Plans
Figure 33. Smith & Nephew plc Recent Developments and Future Plans
Figure 34. Zimmer Biomet Holdings Recent Developments and Future Plans
Figure 35. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Share by Players in 2020
Figure 36. Autologous Matrix-Induced Chondrogenesis (AMIC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share in 2020
Figure 38. Global Top 10 Players Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Share by Type in 2020
Figure 41. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Share Forecast by Type (2021-2026)
Figure 42. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Share by Application in 2020
Figure 43. Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Share Forecast by Application (2021-2026)
Figure 44. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Type (2016-2026)
Figure 45. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Application (2016-2026)
Figure 46. North America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Country (2016-2026)
Figure 47. United States Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Type (2016-2026)
Figure 51. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Application (2016-2026)
Figure 52. Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Country (2016-2026)
Figure 53. Germany Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Region (2016-2026)
Figure 61. China Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Type (2016-2026)
Figure 68. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Application (2016-2026)
Figure 69. South America Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
Buy
